Vericel Co. (NASDAQ:VCEL – Get Free Report) Director Steven C. Gilman sold 5,833 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total transaction of $235,361.55. Following the sale, the director now owns 11,000 shares in the company, valued at approximately $443,850. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Vericel Price Performance
VCEL traded up $2.01 on Friday, reaching $43.36. 289,431 shares of the company’s stock were exchanged, compared to its average volume of 437,657. Vericel Co. has a twelve month low of $30.18 and a twelve month high of $54.10. The stock has a market cap of $2.11 billion, a PE ratio of -4,336.00 and a beta of 1.67. The stock’s fifty day moving average price is $46.75 and its 200-day moving average price is $47.29.
Vericel (NASDAQ:VCEL – Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). Vericel had a return on equity of 0.35% and a net margin of 0.37%. The business had revenue of $52.70 million during the quarter, compared to analyst estimates of $52.59 million. During the same period in the prior year, the business earned ($0.11) earnings per share. The business’s revenue was up 14.8% compared to the same quarter last year. As a group, research analysts predict that Vericel Co. will post 0.12 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analyst Ratings Changes
VCEL has been the subject of several recent analyst reports. Truist Financial lifted their price target on Vericel from $56.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Stephens boosted their price objective on Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. HC Wainwright increased their target price on Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. BTIG Research cut their price target on shares of Vericel from $56.00 to $55.00 and set a “buy” rating for the company in a report on Monday, July 15th. Finally, TD Cowen increased their price objective on shares of Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, August 27th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Vericel presently has a consensus rating of “Moderate Buy” and an average target price of $55.75.
Check Out Our Latest Research Report on VCEL
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Featured Stories
- Five stocks we like better than Vericel
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- How to Invest in Insurance Companies: A Guide
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.